APP Pharmaceuticals, Inc. (Nasdaq:APPX) and Fresenius SE (XETRA:FRE)
have received confirmation that the U.S. Federal Trade Commission (FTC)
has completed its review of the proposed acquisition of APP
Pharmaceuticals by Fresenius Kabi, a business segment of Fresenius SE.
The FTC granted early termination of the waiting period under the
Hart-Scott-Rodino Act without conditions. The German antitrust
authorities had already approved the acquisition.
On July 7, 2008, Fresenius had announced the acquisition of APP
Pharmaceuticals, an important step in the growth strategy of Fresenius
Kabi. With the FTC review complete, Fresenius and APP expect the
transaction to close mid September 2008, subject to certain other
customary closing conditions.
About Fresenius SE
Fresenius is a health care group with international operations,
providing products and services for dialysis, hospital and outpatient
medical care. In 2007, group sales were approximately €
11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees
worldwide. For more information visit the Company’s
website at www.fresenius.com.
About Fresenius Kabi
Fresenius Kabi is the leader in infusion therapy and clinical nutrition
in Europe and in its most important countries of Latin America and Asia
Pacific. Fresenius Kabi’s core product range
includes infusion solutions for fluid substitution, blood volume
expansion and parenteral nutrition, as well as products for enteral
nutrition. Furthermore, the company provides concepts for ambulatory
health care and is focused on managing and providing home therapies.
With its philosophy “Caring for life”
and a comprehensive product portfolio, the company aims at improving the
quality of life of patients all over the world. On June 30, 2008 the
company had 18,323 employees. In 2007, Fresenius Kabi achieved sales of €
2,030 million and an operating profit of € 332
million. Fresenius Kabi AG is a 100 % subsidiary of the health care
group Fresenius SE.
About APP Pharmaceuticals, Inc.
APP is a fully-integrated pharmaceutical company that develops,
manufactures and markets injectable pharmaceutical products with a
primary focus on the oncology, anti-infective, anesthetic/analgesic and
critical care markets.
